Menu

Pharma News

Business Aquisition V13F07

German drugmaker Stada to be sold for over US$5 billion

Home/Pharma News | Posted 02/06/2017

After months of discussions, German generics firm Stada has announced that it will be sold for US$5.63 billion to private equity firms Bain Capital and Cinven.

59 MD002189

Japan’s Sawai to acquire US generics business Upsher-Smith

Home/Pharma News | Posted 19/05/2017

Sawai Pharmaceutical Company Ltd (Sawai) has signed an agreement to purchase the generics section of US firm Upsher-Smith in an attempt to enter the vast American pharmaceuticals market. 

Shaking hands V13D29

Fresenius Kabi to acquire Akorn and Merck KGaA’s biosimilars business

Home/Pharma News | Posted 28/04/2017

Fresenius Kabi, one of the independently operated business segments of global healthcare group Fresenius, announced on 24 April 2017 that it had made two deals ‘to strengthen and diversify’ its business.

Biological large Hanyang Univ V15c13

Samsung BioLogics and Aurobindo investing in biosimilars

Home/Pharma News | Posted 14/04/2017

Both Samsung and Aurobindo see a bright future for biosimilars. Samsung BioLogics, which is the specialized biotechnology arm of Samsung, raised almost US$2 billion in November 2016 via an initial public offering (IPO) that valued the company at US$7.9 billion. This, according to Robert Wessman, Chairman and CEO at Alvogen, ‘underlines the confidence of the market in biosimilar companies’. Especially when considering that Samsung BioLogics only came into existence in 2011 [1].

139 AA007285

Merck KGaA to sell off biosimilars business

Home/Pharma News | Posted 07/04/2017

Germany’s drugmaker Merck KGaA (Merck Group) is to sell its biosimilars division, according to a statement made in its 2016 annual report.

69 MD002136

Australians pay too much for prescription drugs

Home/Pharma News | Posted 24/03/2017

Australians are paying way too much for their prescription drugs, according to a new report released in March 2017 by the Grattan Institute, an independent, non-partisan think tank.

Business Aquisition V13F07

CinnaGen to invest in Turkish pharmaceuticals sector

Home/Pharma News | Posted 10/03/2017

Turkey’s health minister, Mehmet Muezzinoglu, has announced that the country is planning to produce medicines locally by attracting foreign investors. The strategy aims to reduce healthcare spending in the country and reduce its reliance on imports of medicines from foreign countries.

51 MD002353

Intas enters top 20 generics firms through Actavis purchase

Home/Pharma News | Posted 17/02/2017

Intas Pharmaceuticals (Intas) has completed a deal to acquire Actavis UK and Actavis Ireland (Actavis UK and Ireland) from Teva Pharmaceutical (Teva) for over GBP 600 million.

117 MD002146

Baxter expands injectables portfolio with purchase of Claris Injectables

Home/Pharma News | Posted 03/02/2017

US-based Baxter International Inc (Baxter) has announced its acquisition of India’s Claris Injectables Ltd, which will enhance the company’s position in the global injectables market.

Application V15a16

Mabion signs agreement with Mylan for rituximab biosimilar

Home/Pharma News | Posted 20/01/2017

Global specialty pharmaceuticals firm Mylan has reached an agreement with Mabion, a leading biotechnology company in Poland, for the exclusive right to commercialize their rituximab biosimilar candidate in the European Union (EU).

07 AA011110

Eagle moves into biosimilars with Arsia acquisition

Home/Pharma News | Posted 13/01/2017

Specialty pharmaceuticals company Eagle Pharmaceuticals (Eagle) has signed an agreement to acquire Arsia Therapeutics (Arsia), the biotechnology company behind cutting-edge technology that enables intravenous drugs to be administered by injection.

2016 V17A06

Top 10 most read GaBI Online articles in 2016

Home/Pharma News | Posted 06/01/2017

It has once again been a busy year for biosimilars. An important milestone for biosimilars in 2016 was the adoption by the European Medicines Agency (EMA) of new guidance on monitoring biologicals. While the US Food and Drug Administration (FDA) approvals of infliximab and adalimumab biosimilars were also important events in 2016. Other subjects of interest for biosimilars were the differences between biosimilars and reference biologicals, biosimilarity and switching biosimilars. Biosimilars remain the hot topic for GaBI Online during 2016.

138 AA011155

Strategic biologicals alliance between Sanofi and JHL Biotech in China

Home/Pharma News | Posted 06/01/2017

Sanofi and JHL Biotech (JHL) announced on 5 December 2016 that they were forming a strategic biologics alliance in China.  The two companies will be collaborating on the development and commercialization of biological therapeutics in China, with potential for further international expansion.

Shaking hands V13D29

Sun Pharma to acquire Russia’s Biosintez

Home/Pharma News | Posted 09/12/2016

Sun Pharmaceutical Industries (Sun Pharma) announced on 23 November 2016 its acquisition of Russian pharmaceutical company JSC Biosintez at a cost of US$24 million, demonstrating the company’s commitment to the Russian market.

138 AA011155

India’s Cipla to establish biosimilars facility in South Africa

Home/Pharma News | Posted 25/11/2016

Indian generics maker Cipla has announced a deal to set up South Africa’s first biosimilars manufacturing facility, at an estimated cost of over US$91 million.

01 AA007239

Richter and DM Bio make deal for trastuzumab biosimilar

Home/Pharma News | Posted 11/11/2016

Hungary-based Gedeon Richter (Richter) announced on 19 October 2016 that it had signed a technology transfer and in-licensing agreement with South Korea-based biologicals specialist DM Bio for the development and commercialization of DM Bio’s trastuzumab biosimilar.

Application V15a16

China’s CFDA rejects more than 80% of drug applications

Home/Pharma News | Posted 28/10/2016

Data released by China Food and Drug Administration (CFDA) revealed that between January 2015 and January 2016, 1,184 drug applications submitted to CFDA were rejected or withdrawn due to incomplete or fraudulent clinical data.

Shaking hands V13D29

Dr Reddy’s expands collaboration with Amgen in India

Home/Pharma News | Posted 14/10/2016

Generics manufacturer Dr Reddy’s Laboratories (Dr Reddy’s) is expanding its collaboration with US-based biologicals specialist Amgen with an agreement to market and distribute three of Amgen’s biological medicines in India in the therapy areas of oncology and osteoporosis.

10 AA008993

Sun Pharma announces Japanese distribution pact with Mitsubishi Tanabe

Home/Pharma News | Posted 07/10/2016

Sun Pharmaceutical Industries (Sun Pharma) has announced it will transfer marketing authorizations for 14 of its prescription drugs to Mitsubishi Tanabe Pharma (Mitsubishi Tanabe), allowing the company to manufacture and market them in Japan.

117 MD002146

Pfizer antibiotics banned across the EU

Home/Pharma News | Posted 16/09/2016

An inspection by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has resulted in the ban of several drugs produced by a Pfizer manufacturing site in India.